Preclinical Medications Discovery and Abuse Liability Testing for NIDA
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NATIONAL INSTITUTES OF HEALTH OLAO
Contract Value
Not provided
Codes & Classification
Solicitation Number
75N95022C00004
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Classification Code
AN11
Additional Details
The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH) under the Department of Health and Human Services, has issued a presolicitation notice regarding a proposed non-competitive contract action. This notice pertains to a planned sole source modification of Contract No. 75N95022C00004, currently held by Virginia Commonwealth University, for the project titled “Preclinical Medications Discovery and Abuse Liability Testing for NIDA.” The modification seeks to extend the period of performance by an additional 12 months, through February 21, 2027, with all other terms and conditions remaining unchanged.
The primary purpose of this contract extension is to ensure the uninterrupted continuation of critical research activities under NIDA’s Addiction Treatment Discovery Program (ATDP), which operates within the Division of Therapeutics and Medical Consequences (DTMC). The scope of work encompasses preclinical discovery and testing of medications, specifically focusing on evaluating abuse liability—a key step in the development of therapeutics for substance use disorders. The intended outcome is to prevent delays or disruptions in ongoing and upcoming preclinical and clinical trials, thereby supporting the agency’s mission to advance treatment options for addiction.
Key requirements and expected deliverables include ongoing research and testing services that align with the objectives of the Preclinical Medications Discovery and Abuse Liability Testing program. The contract modification is designed to bridge the gap while a new competitive contract is planned and executed, ensuring continuity in the development pipeline for therapeutics.
The procurement is classified under Product Service Code AN11 and NAICS Code 541715, which covers Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). The place of performance is Bethesda, Maryland, USA. Notably, there is no small business set-aside associated with this action, and the procurement is being conducted under the authority of 41 U.S.C. 3304(a)(1), which allows for sole source awards when only one responsible source can satisfy agency requirements. The modification will incorporate all applicable provisions and clauses of the Revolutionary FAR Overhaul (RFO) Initiative, in accordance with Executive Order 14275 and OMB Memorandum M-25-26.
While this is not a solicitation or a request for competitive proposals, interested parties may express their interest and demonstrate their capability to fulfill the requirement. Responses should include detailed information such as unit and list prices, shipping and handling costs, delivery period, prompt payment discount terms, F.O.B. point, Unique Entity ID (UEI), Taxpayer Identification Number (TIN), and certification of business size. All offerors must be registered in the System for Award Management (SAM).
The contracting entity is the NIH Office of Logistics and Acquisition Operations (OLAO), with Shayna Simpson serving as the primary point of contact ([email protected], 301-402-9712). Josh Lazarus is listed as the secondary contact ([email protected]). Responses must be submitted electronically by November 27, 2026, at 1:00 PM Eastern Time, referencing the project title. Mailed and faxed responses will not be accepted.
This presolicitation notice is active and available for review on SAM.gov (Opportunity ID: 54f02db654c1489dadd4275bbb1462d9). Contractors interested in this opportunity should carefully assess their capabilities in preclinical medication discovery and abuse liability testing, as well as their ability to meet the requirements for continuity of research in support of NIDA’s therapeutic development initiatives.